NEXT: Transcribrial Drug Delivery >

CHALLENGES

How Rocket
Science Health

Delivers Impact

Addressing drug-delivery challenges to improve neurological health

Despite a growing number of people living with neurological and mood disorders, treatment of this population has been limited by challenges to the efficacious, safe and non-invasive delivery of central nervous system drugs. Rocket Science Health is seeking to contribute to better health outcomes for this population. Its non-invasive precision drug delivery technology enables efficacious and safe nose-to-brain drug delivery by precisely targeting the olfactory region of the nasal anatomy.

Rocket Health Science | Technology

THE CHALLENGES

Neurological disease and psychiatric disorders are top contributors to the global burden of disease.

Neurological diseases and psychiatric disorders that affect the brain and other parts of the central nervous system (CNS) are highly prevalent and top contributors to the overall global burden of disease.1, 2, 4, 5 The WHO estimates that brain disorders affect nearly 1 billion people worldwide.6 Another estimated 455 million people suffer from mental illness.3

Successful treatment has been limited because of the difficulty in getting therapeutics to the CNS. 

Successful treatment of many neurological and psychiatric disorders has been limited in large part due to the challenging nature of delivering therapeutics to the brain and the rest of the CNS.5 Less than 2% of small molecules and nearly 0% of large molecule therapeutics approved by the FDA can successfully pass the blood-brain barrier (BBB) and blood-cerebrospinal fluid barriers (BCSFB) without complex and often invasive drug-delivery techniques5.

Intranasal drug delivery has seen limited success due to low delivery efficiency to the olfactory region.

Intranasal drug-delivery has been explored as a non-invasive method of direct-to-brain drug delivery to address the problem posed by the BBB and BCSFB, but has seen limited success due to low delivery efficiency to the olfactory region. 7 With current intranasal spray devices, few molecules reach the olfactory mucosa of the upper nasal cavity where they can circumvent the BBB and travel to their targets in the CNS. Rocket Science Health offers a superior solution to achieve efficacious nose-to-brain drug-delivery.

REFERENCES

1. Any Mood Disorder. National Institute of Mental Health. Accessed July 27, 2020. https://www.nimh.nih.gov/health/statistics/any-mood-disorder.shtml

2. Depression. The World Health Organization. Accessed July 27, 2020. https://www.who.int/news-room/fact-sheets/detail/depression

3.Funk M, Drew N, Freeman M, Faydi E. Mental Health and Development: Targeting People with Mental Health Conditions as A Vulnerable Group. Geneva, Switzerland: World Health Organization; 2010. https://apps.who.int/iris/handle/10665/44257

4. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459‐480. Doi:10.1016/S1474-4422(18)30499-X https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30499-X/fulltext

5. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3‐14. Doi:10.1602/neurorx.2.1.3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC539316/

6. WHO. Neurological Disorders: Public Health Challenges. Geneva, Switzerland: World Health Organization, WHO Press; 2006. https://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf

7. Xi J, Zhang Z, Si XA. Improving intranasal delivery of neurological nanomedicine to the olfactory region using magnetophoretic guidance of microsphere carriers. Int J Nanomedicine. 2015;10:1211‐1222. Published 2015 Feb 10. doi:10.2147/IJN.S77520 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334328/

VISIT OUR RESOURCE SECTION